Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aditxt Inc ADTX

Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.


NDAQ:ADTX - Post by User

<< Previous
Bullboard Posts
Next >>
User Avatar Image
(62)
•••
  • IseneschalX
Comment by Iseneschalon Oct 03, 2024 8:20am
23 Views
Post# 36251244

RE:ADTX.....There is a filing that one should be cognizant of..

RE:ADTX.....There is a filing that one should be cognizant of..
Iseneschal wrote: https://www.sec.gov/Archives/edgar/data/1726711/999999999524002845/xslEFFECTX01/primary_doc.xml

It's a double edged sword......most times there should be a major "pump" to inflate the sh price.....some times they drive the sh price down

Ya pays yo money & yo takes yo chances




Right from "the horses mouth"......as I mentioned ; )

 

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

 

2024-10-03 05:15 ET - News Release

 

Acquisition target Evofem reported revenue of $7.8 million for the six months ended June 30, 2024

Acquisition target Appili has received approximately $6.0 million of the total $14.0 million to date in a non-dilutive funding commitment from DoD

Shelf registration statement and resale registration statement for Equity Line of Credit declared Effective by the SEC

Effected a 1-for-40 reverse split of its common stock, which was primarily intended to regain compliance with Nasdaq’s minimum bid price requirement


MOUNTAIN VIEW, Calif. -- (Business Wire)

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today provided an update on its plans for 2024 year-end.


<< Previous
Bullboard Posts
Next >>